Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda

TitleDifferential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda
Publication TypeJournal Article
Year of Publication2013
AuthorsMullis, CE, Munshaw, S, Grabowski, MK, Eshleman, SH, Serwadda, D, Brookmeyer, R, Nalugoda, F, Kigozi, G, Kagaayi, J, Tobian, AA, Wawer, M, Gray, RH, Quinn, TC, Laeyendecker, O
JournalAIDS Research and Human Retroviruses
Date PublishedAug
ISBN Number1931-8405 (Electronic)0889-2229 (Linking)
Accession Number23641870
KeywordsSexual and Reproductive Health

Assays to determine HIV incidence from cross-sectional surveys have exhibited a high rate of false-recent misclassification in Kenya and Uganda where HIV subtypes A and D predominate. Samples from individuals infected with HIV for at least 2 years with known infecting subtype (133 subtype A, 373 subtype D) were tested using the BED-CEIA and an avidity assay. Both assays had a higher rate of false-recent misclassification for subtype D compared to subtype A (13.7% vs. 6.0%, p=0.02 for BED-CEIA; 11.0% vs. 1.5%, p<0.001 for avidity). For subtype D samples, false-recent misclassification by the BED-CEIA was also more frequent in women than men (15.0% vs. 5.6%, p=0.002), and for samples where that had an amino acid other than lysine at position 12 in the BED-CEIA peptide coding region (p=0.002). Furthermore in subtype D-infected individuals, samples misclassified by one assay were 3.5 times more likely to be misclassified by the other assay. Differential misclassification by infecting subtype of long-term infected individuals as recently infected makes it difficult to use these assays individually to estimate population level incidence without precise knowledge of the distribution of these subtypes within populations where subtype A and D cocirculate. The association of misclassification of the BED-CEIA with the avidity assay in subtype D-infected individuals limits the utility of using these assays in combination within this population.